Table 3. Descriptive Comparison of Retention Across Treatment Modalities Among VHA Patients Who Received Buprenorphine for OUD in the Year Following COVID-19–Related Changes.
| All patients (n = 17 182) | Patients with any telehealth visits (n = 15 071) | |||||
|---|---|---|---|---|---|---|
| ≥1 Video or telephone visit, No. (%) | Only in-person visits, No. (%) | P valuea | ≥1 Video visit, No. (%) | ≥1 Telephone visit; no video, No. (%) | P valuea | |
| Initiated in year following COVID-19 (n = 4338 among all patients) | ||||||
| Retained ≥90 d | 1024 (32.2) | 294 (25.4) | <.001 | 565 (37.2) | 459 (27.7) | <.001 |
| Not retained ≥90 d | 2156 (67.8) | 864 (74.6) | 955 (62.8) | 1201 (72.3) | ||
| Initiated prior to COVID-19 (n = 12 844 among all patients) | ||||||
| Retained ≥90 d | 6072 (51.1) | 410 (43.0) | <.001 | 2610 (51.9) | 3462 (50.4) | .09 |
| Not retained ≥90 d | 5819 (48.9) | 543 (57.0) | 2417 (48.1) | 3402 (49.6) | ||
a
P value from χ2 test.